# Nvidia vs. Eli Lilly: Which Stock Wins Next Decade?

> Nvidia's AI infrastructure and Eli Lilly's GLP-1 drugs both surged, but which stock has the cleaner path to 10-year growth?
- Title: Nvidia vs. Eli Lilly: Which Stock Wins Next Decade? | Shortify
- Summary: Nvidia's AI infrastructure and Eli Lilly's GLP-1 drugs both surged, but which stock has the cleaner path to 10-year growth? Nvidia's platform-driven AI…
- Keywords: nvidia, eli lilly, glp-1, mounjaro, zepbound, foundeo, retatrutide, blackwell ultra, vera rubin, data center, ai infrastructure, glp-1 medicines
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/09/21/nvidia-vs-eli-lilly-id-choose-this-stock-for-the-next-decade
- Author: Vandita Jadeja
- Published: 2026-09-21T14:30:10+00:00
- Read time: 1 min
- Topics: nvidia, eli lilly, glp-1, mounjaro, zepbound, foundeo, retatrutide, blackwell ultra, vera rubin, data center, ai infrastructure, glp-1 medicines
## Nvidia's AI Surge
Nvidia reported $96.22B Q2 revenue, up 105.8% YoY, with data center driving $89.02B.

> AI has reached its inflection point. It's doing useful work. Its tokens are productive and profitable. Now, compute is revenue.
## Eli Lilly's Drug Boom
Eli Lilly reported $22.97B Q2 revenue, up 47.7%, with Mounjaro and Zepbound generating $14.9 billion.

> Lilly's oral GLP-1 Foundeo expanded its U.S. prescriber base from 8,000 to 36,000 in a single quarter.
## Nvidia's Platform Edge
Vera Rubin production ramps to $40 billion revenue opportunity, up from Blackwell Ultra's $25 billion.

> Hyperscaler capex is projected to hit nearly 800 billion in 2026 and 1.3 trillion in 2027.
## Lilly's Drug Pipeline
Retatrutide, a next-gen weight-loss drug, shows weight loss approaching bariatric surgery levels.

> Retatrutide produced weight loss 'approaching bariatric surgery levels' with a BLA filing planned for Q1 2027.
## Risk Comparison
Nvidia faces supply constraints and balance sheet scrutiny, while Lilly struggles with drug concentration and pricing.

> U.S. price fell 9% ex-rebates, and concentration in two drugs is a real vulnerability.
## Long-Term Outlook
Nvidia's forward P/E of 23 with triple-digit growth and 60.4% margins outperforms Lilly's defensive profile.

> For a ten-year lens, Nvidia screens strongest. The forward P/E of 23 against triple-digit growth and a 60.4% operating margin is hard to argue with.
## Key takeaway

Nvidia's platform-driven AI growth outperforms Eli Lilly's drug pipeline for long-term value.